Patient data
| Patient . | Age, y . | Malignancy . | No. of prior therapies . | Total no. of infused cells/kg, ×107 . | Percentage of infused cells CAR+ . | No. of infused CAR+ cells/kg ×107 . | Infused cells CD4/CD8 ratio . | Doses of IL-2 administered . | Response and time since treatment, mo* . |
|---|---|---|---|---|---|---|---|---|---|
| 1a† | 47 | Follicular lymphoma | 4 | 0.5 | 64 | 0.3 | 29/63 | 8 | PR (7) |
| 1b† | 48 | Follicular lymphoma | 5 | 2.1 | 63 | 1.3 | 19/71 | 10 | PR (18+) |
| 2 | 48 | Follicular lymphoma | 5 | 0.5 | 65 | 0.3 | 23/73 | 9 | NE (died with influenza) |
| 3 | 61 | CLL | 3 | 2.5 | 45 | 1.1 | 35/53 | 2 | CR (15+) |
| 4 | 55 | Splenic marginal zone lymphoma | 3 | 2.0 | 53 | 1.1 | 72/24 | 4 | PR (12) |
| 5 | 54 | CLL | 4 | 0.6 | 50 | 0.3 | 87/12 | 2 | SD (6) |
| 6 | 57 | CLL | 7 | 5.5 | 30 | 1.7 | 37/57 | 1 | PR (7) |
| 7 | 61 | CLL | 4 | 5.4 | 51 | 2.8 | 58/41 | 2 | PR (7+) |
| 8 | 63 | Follicular lymphoma | 7 | 4.2 | 71 | 3.0 | 54/43 | 5 | PR (8+) |
| Patient . | Age, y . | Malignancy . | No. of prior therapies . | Total no. of infused cells/kg, ×107 . | Percentage of infused cells CAR+ . | No. of infused CAR+ cells/kg ×107 . | Infused cells CD4/CD8 ratio . | Doses of IL-2 administered . | Response and time since treatment, mo* . |
|---|---|---|---|---|---|---|---|---|---|
| 1a† | 47 | Follicular lymphoma | 4 | 0.5 | 64 | 0.3 | 29/63 | 8 | PR (7) |
| 1b† | 48 | Follicular lymphoma | 5 | 2.1 | 63 | 1.3 | 19/71 | 10 | PR (18+) |
| 2 | 48 | Follicular lymphoma | 5 | 0.5 | 65 | 0.3 | 23/73 | 9 | NE (died with influenza) |
| 3 | 61 | CLL | 3 | 2.5 | 45 | 1.1 | 35/53 | 2 | CR (15+) |
| 4 | 55 | Splenic marginal zone lymphoma | 3 | 2.0 | 53 | 1.1 | 72/24 | 4 | PR (12) |
| 5 | 54 | CLL | 4 | 0.6 | 50 | 0.3 | 87/12 | 2 | SD (6) |
| 6 | 57 | CLL | 7 | 5.5 | 30 | 1.7 | 37/57 | 1 | PR (7) |
| 7 | 61 | CLL | 4 | 5.4 | 51 | 2.8 | 58/41 | 2 | PR (7+) |
| 8 | 63 | Follicular lymphoma | 7 | 4.2 | 71 | 3.0 | 54/43 | 5 | PR (8+) |
PR indicates partial remission; NE, not evaluable; CR, complete remission; SD, stable disease; and CLL, chronic lymphocytic leukemia.
Time since treatment is in months; + indicates an ongoing response as of the time of writing. The body surface area of each patient is given in supplemental Table 2.
Patient 1 was treated twice. His first treatment has been previously reported (21).